Inventor · disambiguated record
Huawei Qiu
Also filed as: QIU HUAWEI
45 granted patents·28 pending applications·201 citations·filing 2004–2025
98Inventor score
Top patents by PatentIndex Score
73 records- 0197US9790268B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2014·Granted Oct 17, 2017·29 cites·39 claims
- 0296US11130816B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2019·Granted Sep 28, 2021·6 cites·20 claims
- 0396US10836813B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2017·Granted Nov 17, 2020·11 cites·23 claims
- 0495US12110338B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2021·Granted Oct 8, 2024·2 cites·29 claims
- 0595US11807690B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2019·Granted Nov 7, 2023·4 cites·17 claims
- 0695US11053294B2Masked cytokine polypeptidesXILIO DEV INC·Filed 2020·Granted Jul 6, 2021·13 cites·15 claims
- 0795US10995148B2Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2015·Granted May 4, 2021·8 cites·39 claims
- 0894US12162933B2Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2023·Granted Dec 10, 2024·1 cites·9 claims
- 0994US11613576B2Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2020·Granted Mar 28, 2023·3 cites·29 claims
- 1094US10494439B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2017·Granted Dec 3, 2019·9 cites·19 claims
- 1194US9701753B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2014·Granted Jul 11, 2017·16 cites·25 claims
- 1294US9580511B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2014·Granted Feb 28, 2017·17 cites·47 claims
- 1393US11325971B2scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2019·Granted May 10, 2022·4 cites·15 claims
- 1493US11242384B2Anti-TGF-beta antibodies and their useSANOFI SA·Filed 2020·Granted Feb 8, 2022·4 cites·14 claims
- 1593US10214589B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2017·Granted Feb 26, 2019·9 cites·18 claims
- 1692US11976112B2scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2022·Granted May 7, 2024·1 cites·8 claims
- 1792US11866476B2Masked IL-2-Fc fusion polypeptidesXILIO DEV INC·Filed 2022·Granted Jan 9, 2024·1 cites·10 claims
- 1892US11186638B2Anti-αβTCR antibodyGENZYME CORP·Filed 2018·Granted Nov 30, 2021·10 cites·11 claims
- 1992US10308917B2Nucleotide sequences encoding VEGF antagonist compositions of FLT-1 and uses thereofGENZYME CORP·Filed 2016·Granted Jun 4, 2019·7 cites·13 claims
- 2091US11834495B2Modified-IgG antibodies that bind transforming growth factor-BETA1 with high affinity, avidity and specificityGENZYME CORP·Filed 2022·Granted Dec 5, 2023·1 cites·11 claims
- 2190US11718655B2Masked interleukin-12 polypeptidesXILIO DEV INC·Filed 2022·Granted Aug 8, 2023·1 cites·9 claims
- 2290US11325970B2Modified-IgG antibodies that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2016·Granted May 10, 2022·4 cites·20 claims
- 2390US2025066497A1Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2024·Application pending·0 cites
- 2488US11697690B2Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2021·Granted Jul 11, 2023·1 cites·20 claims
- 2588US2024182595A1Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2023·Application pending·0 cites
- 2687US12473356B2scFv-Fc dimers that bind transforming growth factor-β1 with high affinity, avidity and specificityGENZYME CORP·Filed 2024·Granted Nov 18, 2025·0 cites·8 claims
- 2787US9441029B2VEGF antagonist compositions and uses thereofSTEFANO JAMES·Filed 2011·Granted Sep 13, 2016·7 cites·32 claims
- 2886US10766955B2Anti-TGF-β antibodies and their useSANOFI SA·Filed 2018·Granted Sep 8, 2020·4 cites·33 claims
- 2985US10508146B2ScFv-Fc dimers that bind transforming growth factor-BETA1 with high affinity, avidity and specificityGENZYME CORP·Filed 2016·Granted Dec 17, 2019·4 cites·12 claims
- 3085US2025179163A1MODIFIED-IgG ANTIBODIES THAT BIND TRANSFORMING GROWTH FACTOR-BETA1 WITH HIGH AFFINITY, AVIDITY AND SPECIFICITYGENZYME CORP·Filed 2024·Application pending·0 cites
- 3182US12227573B2Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2023·Granted Feb 18, 2025·0 cites·45 claims
- 3281US10844115B2Bone-targeting antibodiesGENZYME CORP·Filed 2018·Granted Nov 24, 2020·2 cites·6 claims
- 3381US2024059793A1Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2023·Application pending·0 cites
- 3481US2024117071A1Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2023·Application pending·0 cites
- 3581US2025026821A1Anti-tgf-beta antibodies and their useSANOFI SA·Filed 2024·Application pending·0 cites
- 3680US10017573B2Anti-αβTCR antibodySNELL DANIEL·Filed 2012·Granted Jul 10, 2018·8 cites·12 claims
- 3780US2025074975A1Bone-Targeting AntibodiesGENZYME CORP·Filed 2024·Application pending·0 cites
- 3876US2024218051A1Modified binding polypeptides for optimized drug conjugationGENZYME CORP·Filed 2023·Application pending·0 cites
- 3976US2023126645A1Thyroid stimulating hormone compositionsGENZYME CORP·Filed 2022·Application pending·0 cites
- 4075US12049496B2Anti-TGF-beta antibodies and their useSANOFI SA·Filed 2021·Granted Jul 30, 2024·0 cites·10 claims
- 4175US11827686B2Masked cytokine polypeptidesXILIO DEV INC·Filed 2021·Granted Nov 28, 2023·0 cites·9 claims
- 4275US11827685B2Masked cytokine polypeptidesXILIO DEV INC·Filed 2021·Granted Nov 28, 2023·0 cites·18 claims
- 4374US2022002370A1Masked cytokine polypeptidesXILIO DEV INC·Filed 2019·Application pending·0 cites
- 4473US2023391849A1Modified binding polypeptides for optimized drug conjugationGENZYME CORP·Filed 2023·Application pending·0 cites
- 4572US12503498B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2020·Granted Dec 23, 2025·0 cites·17 claims
- 4672US9708407B2Anti-CD52 antibodiesGENZYME CORP·Filed 2014·Granted Jul 18, 2017·2 cites·45 claims
- 4771US2025250338A1Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2025·Application pending·0 cites
- 4871US2025250337A1Trispecific binding proteins, methods, and uses thereofSANOFI SA·Filed 2025·Application pending·0 cites
- 4970US12227560B2Anti-CHIKV antibodies and uses thereofSANOFI SA·Filed 2022·Granted Feb 18, 2025·0 cites·22 claims
- 5070US7527956B2Modified human acid sphingomyelinase having increased activity, and methods for making the sameGENZYME CORP·Filed 2004·Granted May 5, 2009·11 cites·14 claims
Showing the top 50 of 73 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Huawei Qiu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →